Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.68 |
| ▸ | MAOB | P27338 | 8/20 | 0.60 |
| ▸ | MAOA | P21397 | 7/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYBB | P04839 | 1/20 | 0.45 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.45 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10651353 | 0.90 | KIF11 (0.58) | KIF11MAOBMAOAEPHX2HTT | |
| SCHEMBL4596362 | 0.89 | KIF11 (0.61) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL4888650 | 0.85 | KIF11 (0.67) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL12922252 | 0.85 | EPHX2 (0.63) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL11242330 | 0.84 | MAOB (0.58) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL13662106 | 0.80 | EPHX2 (0.56) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL1878456 | 0.79 | CYP11B1 (0.62) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL3380357 | 0.79 | KIF11 (0.52) | KIF11 | |
| SCHEMBL5751107 | 0.79 | MAOB (0.64) | KIF11MAOBMAOAEPHX2CYP11B1 | |
| SCHEMBL6752830 | 0.78 | MAOB (0.66) | KIF11MAOBMAOAEPHX2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112262145-B | 2-aminopyrimidine derivative and preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| CN-112262145-A | 2-aminopyrimidine derivatives, preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2021-01-22 | — | — | CN | disclosed |
| US-6713468-B2 | AS ANTICONVULSANTS; FOR THERAPY AND PROPHYLAXIS OF ISCHAEMIAS, ANOXIA, NEURODEGENERATIVE DISEASES | AVENTIS PHARMA S.A. (FR) | 2004-03-30 | — | — | US | disclosed |
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | RHONE-POULENC RORER S.A. | 2003-03-20 | — | — | US | disclosed |
| US-6448241-B1 | THESE COMPOUNDS ARE ANTICONVULSANTS AND INTERFERE WITH GLUTAMATERGIC TRANSMISSION AND ARE THEREFORE USEFUL FOR THE TREATMENT OR PREVENTION OF ALL ISCHAEMIAS FOLLOWING CEREBROVASCULAR ACCIDENTS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-0966473-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-07-24 | — | — | EP | disclosed |
| US-6423715-B1 | ANTICONVULSANTS | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6288075-B1 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM, BRAIN, AND CARDIOVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-0966473-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998038194-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055031-A1 | Methods of using thiazolobenzoheterocycles | SLCO2B1, SLCO1B1, CYP21A2 | KIF11 4115/4885MAOB 495/4885MAOA 1637/4885 |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | IDH1, IDH2, IDH3B | KIF11 3797/4885MAOB 3024/4885MAOA 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.